Recombinant PCSK9 (Bococizumab Biosimilar) anticorps
Research Grade
Reactivité: Humain
ELISA
Hôte: Mammalian Cells
Monoclonal
unconjugated
Recombinant Antibody
-
- Antigène Tous les produits PCSK9 (Bococizumab Biosimilar)
- PCSK9 (Bococizumab Biosimilar)
- Type d'anticorp
- Recombinant Antibody
- Reactivité
- Humain
-
Hôte
-
Mammalian Cells
- Expression System
- Mammalian cells
-
Clonalité
- Monoclonal
-
Conjugué
- Cet anticorp PCSK9 (Bococizumab Biosimilar) est non-conjugé
- Application
- ELISA
- Fonction
- Bococizumab Biosimilar - Anti-PCSK9, NARC1, PC9 mAb
- Attributs du produit
- Antibody Type: IgG2-kappa
- Purification
- Recombinant antibody expressed in mammalien cells and purified.
- Classe de qualité
- Research Grade
- Isotype
- IgG2
-
-
- Restrictions
- For Research Use only
-
- Buffer
- PBS pH 7.5
- Stock
- -80 °C
- Stockage commentaire
- store at -80°C
-
- Antigène
- PCSK9 (Bococizumab Biosimilar)
- Abstract
- PCSK9 (Bococizumab Biosimilar) Produits
- Classe de substances
- Biosimilar
- Sujet
-
PF-04950615,RN-316
Bococizumab is a monoclonal antibody that was development by Pfizer targeting proprotein convertase subtilisin kexin type 9 (PCSK9). Bococizumab has been investigated for the treatment and prevention of Dyslipidemia, Hyperlipidemia, Hypercholesterolemia, Cardiovascular Disease, and Heterozygous Familial Hypercholesterolemia. - Numéro CAS
- 1407495-02-6
-
Vous êtes ici:
